A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants

NCT06092931 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Participants

Interventions

DRUG: DC-806
DRUG: Midazolam
DRUG: Repaglinide
DRUG: Digoxin
DRUG: Rosuvastatin

Sponsor

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company